Liquid Biopsy Market Size

Global Liquid Biopsy Market size was valued at USD 7.6 billion in 2023 and is poised to grow from USD 8.75 billion in 2024 to USD 26.95 billion by 2032, growing at a CAGR of 15.1% during the forecast period (2025-2032). 

Major players include F. Hoffmann-La Roche Ltd (Switzerland) , Thermo Fisher Scientific Inc. (US) , Illumina, Inc. (US) , Guardant Health, Inc. (US) , Biocept, Inc. (US) , Sysmex Corporation (Japan) , Menarini Silicon Biosystems (Italy) , Natera, Inc. (US) , Biocartis Group NV (Belgium) , Personal Genome Diagnostics Inc. (US) , Bio-Rad Laboratories, Inc. (US) , OncoCyte Corporation (US) , Adaptive Biotechnologies Corporation (US) , Angle plc (United Kingdom) , Epic Sciences, Inc. (US) , NEOGENOMICS LABORATORIES (US) , CellMax Life (US) , MENARINI-SILICON BIOSYSTEMS (Italy) , LUNGLIFE AI, INC. (US) , VORTEX BIOSCIENCES (US)

Next-generation sequencing (NGS) and polymer chain reaction (PCR) technologies have greatly improved the sensitivity and specificity of liquid screening tests, and increased adoption in clinical settings. 

The combination of AI and ML technologies is transforming the liquid biopsy market. AI and ML algorithms are used to analyze complex data from liquid biopsy tests, identifying patterns and biomarkers associated with different cancers. This combination increases the accuracy, predictive power and performance of liquid biopsy tests for detection.

North America dominated the market with a 50.76% revenue percentage in 2023, driven with the aid of heavy funding and the entry of numerous biotechnology corporations carrying out advanced trials.

The global liquid biopsy market is projected to grow at a compound annual growth rate (CAGR) of approximately 10.7% through 2032, reflecting rising demand for non-invasive diagnostic solutions and precision oncology.

Liquid biopsy adoption is driven by its non-invasive nature, real-time disease monitoring, and rising demand for early cancer detection and personalized therapies.

Personalized medicine drives the liquid biopsy market by enabling tailored treatments through real-time tumor mutation and drug resistance monitoring.

Next-generation sequencing (NGS) is a cornerstone technology in liquid biopsy diagnostics. It enables comprehensive genomic analysis by detecting circulating tumor DNA (ctDNA) and other molecular alterations in blood samples.

The main applications of liquid biopsy in cancer diagnostics include early detection, treatment selection, and monitoring of minimal residual disease (MRD). These applications are particularly valuable when conventional tissue samples are not accessible or when frequent monitoring is required throughout a patient’s treatment journey. 

In liquid biopsy tests, commonly analyzed biomarkers include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and various protein markers such as PSA, CA-19-9, and CA-125. These biomarkers offer critical insights into tumor dynamics and can guide clinical decisions effectively. 

The future of liquid biopsy is being shaped by recent innovations like the development of highly sensitive epigenetic ctDNA assays that detect cancer at early stages. Notable partnerships, such as those involving Guardant Health, are also accelerating the adoption and global accessibility of liquid biopsy technologies.